New combo therapy targets genetic flaw in Tough-to-Treat cancers
NCT ID NCT07417501
Summary
This study is testing whether a combination of two drugs—lenvatinib (a pill) and a PD-1 inhibitor (an immunotherapy given by IV)—can help control advanced solid tumors that have a specific genetic feature called '11q13 amplification.' The main goals are to see if tumors shrink or stop growing and to monitor side effects. All 60 participants will receive the same drug combination and be closely monitored with scans and checkups.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital
Wuhan, Hubei, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.